• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 164
  • 32
  • 27
  • 11
  • 9
  • 4
  • 4
  • 4
  • 4
  • 3
  • 2
  • 2
  • 1
  • 1
  • 1
  • Tagged with
  • 298
  • 271
  • 258
  • 38
  • 36
  • 34
  • 30
  • 30
  • 29
  • 27
  • 26
  • 26
  • 25
  • 23
  • 22
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
281

Propriétés biologiques du récepteur TLR3 dans les carcinomes des voies aérodigestives supérieures : contribution à l’oncogénèse et intérêt comme cible thérapeutique / Biological properties of the TLR3 receptor in Head and Neck carcinomas : oncogenic role and potential as a therapeutic target

Verillaud, Benjamin 06 February 2015 (has links)
Contexte. Les carcinomes des voies aérodigestives supérieures (VADS) arrivent en 6ème position parmi les cancers les plus fréquents au niveau mondial. La fonction du récepteur TLR3 dans les cellules de carcinomes des VADS est encore très mal comprise. Objectifs et méthodes. 1) Déterminer le niveau d’expression du récepteur TLR3 dans les lignées et les biopsies de carcinomes des VADS par western blot et par immunohistochimie. 2) Etudier le rôle de TLR3 dans la croissance tumorale de ces tumeurs, en utilisant notamment des lignées invalidées de façon conditionnelle pour TLR3. 3) Evaluer in vitro les effets cytotoxiques de ligands artificiels de TLR3 soit seuls, soit utilisés en combinaisons avec un inhibiteur d’IAP (inhibitor of apoptosis protein).Résultats. La protéine TLR3 est détectée à un niveau élevé en western blot dans les lignées de carcinomes des VADS étudiées, comparativement à un panel d’autres tumeurs épithéliales humaines. TLR3 est également constamment détecté en immunohistochimie dans les biopsies. TLR3 semble jouer un rôle dans la croissance tumorale des carcinomes des VADS : dans certaines conditions de culture (culture en hypoxie ou en milieu pauvre en SVF et en nutriments), la stimulation de TLR3 par un ligand exogène, le poly(A:U), favorise la croissance des cellules tumorales. Nous avons étudié l’effet de la stimulation de TLR3 sur le métabolisme glucidique dans ces mêmes cellules en utilisant un appareil de type Seahorse® qui mesure la consommation d’oxygène et la production de protons à partir de cellules cultivées en microplaques. Ces expériences montrent que la stimulation de TLR3 fait augmenter l’activité des voies du métabolisme cellulaire anaérobie (glycolyse extra-mitochondriale). Une étude métabolomique a mis en évidence des différences significatives dans le profil métabolique des cellules tumorales stimulées par le poly(A:U) comparativement aux cellules non traitées. Par ailleurs, nous avons montré que la stimulation de TLR3 permettait de détecter le facteur de transcription HIF1 en Western blot, même en conditions normoxiques. Sachant que des ARN libérés par des cellules en état de nécrose peuvent stimuler TLR3, il est tentant de penser que ce récepteur pourrait favoriser la survie des cellules malignes en zone hypoxique au voisinage de cellules nécrotiques. Néanmoins, l’expression de TLR3 représente aussi un facteur de vulnérabilité pour les cellules de carcinome des VADS : en effet les ligands artificiels de TLR3 utilisés en combinaison avec un inhibiteur d’IAP (Inhibitor of Apoptosis Protein) produisent des effets cytotoxiques sur les lignées de carcinomes des VADS étudiées. / Background. Head and Neck (HN) carcinomas are the 6th most frequent type of cancer worldwide. The role of the TLR3 receptor in HN carcinomas remains poorly understood.Objectives and Methods. 1) To assess the expression level of TLR3 in HN carcinoma cell lines and biopsies by Western blot and immunohistochemistry, respectively. 2) To study the role of TLR3 in tumour growth using specific cell lines with conditional knock-down of TLR3. 3). To assess in vitro the cytotoxic effects of artificial ligands of TLR3 used either alone or in combination with an IAP (inhibitor of apoptosis protein) inhibitor.Results. TLR3 protein was detected at a high level by Western blot analysis in HN carcinoma cell lines, by comparison with a panel of other human epithelial cancer cell lines. TLR3 was also consistently detected by immunohistochemistry in tumour biopsies. TLR3 seem to play a role in HN carcinoma cell growth: under certain culture conditions (hypoxic or low fetal calf serum/low nutrient culture conditions), TLR3 stimulation by a synthetic ligand, the poly(A:U), favours tumour cell growth. We investigated the effects of TLR3 stimulation on glucose metabolism using a Seahorse® analyzer, which measures the oxygen consumption and the proton production in living cells. Our results indicate that TLR3 stimulation induces an increase in anaerobic metabolism (extra-mitochondrial glycolysis). A metabolomic study revealed significant changes in the metabolic profile of cancer cells treated by poly(A:U) by comparison with untreated cells. We also showed that under TLR3 stimulation, HIF1 became detectable by Western blot analysis, even in normoxia. Given the fact that RNA fragments released by dying cells are able to trigger TLR3, one can assume that TLR3 might favour cancer cell survival in hypoxic areas located near the necrotic core of the tumour. However, TLR3 expression is also a factor of vulnerability for HN carcinoma cells: indeed, the combination of TLR3 artificial ligands with an IAP inhibitor has a strong cytotoxic effect on HN carcinoma cells in vitro.
282

Facteurs associés à l’infection au virus Epstein-Barr (VEB) post-greffe chez les enfants recevant des greffes de cellules souches hématopoïétiques (GCSH)

Enok Bonong, Pascal Roland 08 1900 (has links)
La greffe de cellules souches hématopoïétiques (CSH) constitue une avancée thérapeutique considérable dans le traitement de maladies hématologiques et non hématologiques. Toutefois, malgré qu’elle sauve des vies, elle n’est pas sans risque. Le syndrome lymphoprolifératif post-transplantation (SLPT) est l’une des complications qui peut survenir après ce type de greffe avec un risque de mortalité pouvant atteindre 80% en l’absence de traitement. Par ailleurs, les traitements disponibles pour limiter le développement de ce syndrome ne sont pas sans effets néfastes. Le SLPT est surtout une conséquence d’une primo-infection ou d’une réactivation non-contrôlée du virus d’Epstein-Barr (VEB). Au moins 90% des adultes sont porteurs du VEB alors que ce pourcentage est d’environ 50-70% chez les enfants. Il est important de bien comprendre les facteurs de risque de l’infection active du VEB et du SLPT pour une meilleure gestion des greffés. Cette thèse a pour objectif de contribuer aux connaissances quant aux déterminants du VEB et du SLPT chez les greffés pédiatriques de CSH. Dans un premier temps, une revue systématique combinée à une méta-analyse a été réalisée pour élaborer un portrait exhaustif des facteurs de risque connus du VEB et du SLPT chez les greffés adultes et pédiatriques de CSH. Ensuite, à l’aide d’une étude de cohorte prospective multicentrique canadienne qui a enrôlé 156 patients pédiatriques greffés de CSH, le lien entre la transfusion de produits sanguins et l’infection VEB post-greffe a été analysé. Finalement, l’étude de cohorte multicentrique a aussi permis d’explorer des nouveaux facteurs de risque des évènements liés au VEB allant de l’ADNémie VEB à la suspicion du SLPT. Les résultats de la revue systématique et de la méta-analyse ont montré que l’utilisation de la globuline antithymocyte (ATG) pour prévenir la maladie du greffon contre l’hôte est le principal facteur impliqué dans la survenue post-greffe des infections actives du VEB et du SLPT. La forte hétérogénéité entre les études a limité la comparaison des résultats et très peu d’études portaient exclusivement sur les patients pédiatriques. D’autre part, l’analyse statistique au sein de la cohorte multicentrique n’a pas révélé une augmentation statistiquement significative du risque d’infection du VEB post-greffe associé à la transfusion. Toutefois, une analyse de génotypage du virus a indiqué que la transfusion serait très probablement liée à la primo-infection VEB d’un patient séronégatif, et ce malgré la leucoréduction (qui élimine virtuellement la présence des virus associés aux composantes cellulaires des produits sanguins). Par ailleurs, nos analyses dans la cohorte multicentrique ont corroboré l’association entre l’ATG et les évènements liés au VEB post-greffe et mis en relief deux nouvelles associations. Le mycophénolate mofétil, un médicament utilisé pour prévenir la maladie du greffon contre l’hôte, limiterait le risque des évènements liés au VEB par son action antiproliférative des lymphocytes T et B (incluant ceux infectés par le VEB), tandis que les filles seraient plus à risque des formes relativement sévères de l’infection du VEB post-greffe que les garçons. Le rationnel autour de cette dernière association n’est pas connu. Des nouvelles recherches permettront d’apprécier la reproductibilité de ces résultats. / Hematopoietic stem cell transplantation (HSC) constitutes a notable therapeutic advance in the treatment of hematological and non-hematological diseases. However, despite saving lives, it is not without risk. Post-transplant lymphoproliferative disease (PTLD) is one of the complications that can occur after this type of transplant with a mortality risk of up to 80% if left untreated. Moreover, the treatments available to limit the development of this disease are not without harmful effects on transplant recipients. PTLD is predominantly a consequence of primary infection or uncontrolled reactivation of Epstein-Barr virus (EBV). At least 90% of adults are carriers of EBV, compared to around 50-70% in the pediatric population. It is important to understand the risk factors for active EBV infection and PLTD in order to better manage transplant recipients. This thesis aims to contribute to knowledge on the determinants of active EBV infection and PTLD in pediatric HSC transplant recipients. A systematic review combined with a meta-analysis was carried out to develop a comprehensive portrait of the known risk factors for EBV and PTLD in adult and pediatric HSC transplant recipients. Then, using a Canadian multicenter prospective cohort study that enrolled 156 pediatric HSC transplant patients, the link between blood product transfusion and post-transplant EBV infection was analyzed. Finally, the multicenter cohort study also explored new risk factors for EBV-related events ranging from EBV DNAemia to suspicion of PTLD. The results of the systematic review and the meta-analysis revealed that the use of anti-thymocyte globulin (ATG) to prevent graft-versus-host disease is the main factor implicated in the post-transplant occurrence of active EBV infection and PTLD. The high heterogeneity between studies limited the comparison of results and very few studies focused exclusively on pediatric patients. On the other hand, statistical analysis within the multicenter cohort did not reveal a significant increase in the risk of post-transplant EBV infection associated with transfusion. However, genotyping analysis of viral strains from blood donors of an EBV-negative patient who received an EBV-negative graft indicated that one of the blood donors was the source of the primary EBV infection in the patient, despite leukoreduction (which virtually eliminates the presence of cell-associated viruses in blood products). Furthermore, our analyses in the multicenter cohort corroborated the association between ATG and post-transplant EBV-related events, and highlighted two new associations. First, mycophenolate mofetil, a drug used to prevent graft-versus-host disease, is believed to reduce the risk of EBV-related events through its antiproliferative action on T and B lymphocytes (including EBV-infected B cells). Second, girls are more at risk of relatively severe forms of post-transplant EBV infection than boys. The rationale behind this latter association is unknown. New research will make it possible to assess the reproducibility of these results.
283

Associations Between Rheumatoid Arthritis and Malignant Lymphomas

Baecklund, Eva January 2005 (has links)
<p>Patients with rheumatoid arthritis (RA) are at increased risk of developing malignant lymphoma, although details about this association remain unclear. The aims of this thesis were to investigate risk factors for lymphoma in patients with RA and to characterize these lymphomas regarding subtype, presence of Epstein-Barr virus (EBV), clinical manifestations and prognosis. </p><p>The Swedish hospital discharge register and the cancer register were used to identify RA patients with lymphoma. Two case-control studies were performed, one smaller including RA patients with lymphoma hospitalised in Uppsala health care region 1964-1983 (n=41) and one larger study of hospitalised RA patients with lymphoma in Sweden 1964-1995 (n=378). RA patients from the same cohorts, but without lymphoma, were matched as controls. Medical records for cases and controls were scrutinized for exposure information. The lymphoma tissues were reclassified according to the WHO classification, and presence of EBV was analysed by EBER in situ hybridisation.</p><p>The most important risk factor for lymphoma development was high RA disease activity. No association was determined between treatment with traditional disease modifying drugs, non-steroidal anti-inflammatory drugs, aspirin, peroral and intra-articular corticosteroids and lymphoma risk. Diffuse large B-cell lymphoma (DLBCL) was more frequent in RA patients than in lymphoma patients in the general population and displayed stronger association with RA disease activity than other lymphoma subtypes. RA patients with DLBCL had increased extranodal involvement and more advanced lymphoma stage at presentation than DLBCL patients in general, and the prognosis was poor. </p><p>A further subdivision of DLBCL into germinal centre (GC) and non-GC subtypes by the expression patterns of CD10, bcl-6 and IRF-4 showed a predominance of the non-GC subtype. This suggested peripheral activated B-cells as the cells of origin in these lymphomas. </p><p>The presence of EBV was low in lymphomas in RA patients (12%). </p>
284

Associations Between Rheumatoid Arthritis and Malignant Lymphomas

Baecklund, Eva January 2005 (has links)
Patients with rheumatoid arthritis (RA) are at increased risk of developing malignant lymphoma, although details about this association remain unclear. The aims of this thesis were to investigate risk factors for lymphoma in patients with RA and to characterize these lymphomas regarding subtype, presence of Epstein-Barr virus (EBV), clinical manifestations and prognosis. The Swedish hospital discharge register and the cancer register were used to identify RA patients with lymphoma. Two case-control studies were performed, one smaller including RA patients with lymphoma hospitalised in Uppsala health care region 1964-1983 (n=41) and one larger study of hospitalised RA patients with lymphoma in Sweden 1964-1995 (n=378). RA patients from the same cohorts, but without lymphoma, were matched as controls. Medical records for cases and controls were scrutinized for exposure information. The lymphoma tissues were reclassified according to the WHO classification, and presence of EBV was analysed by EBER in situ hybridisation. The most important risk factor for lymphoma development was high RA disease activity. No association was determined between treatment with traditional disease modifying drugs, non-steroidal anti-inflammatory drugs, aspirin, peroral and intra-articular corticosteroids and lymphoma risk. Diffuse large B-cell lymphoma (DLBCL) was more frequent in RA patients than in lymphoma patients in the general population and displayed stronger association with RA disease activity than other lymphoma subtypes. RA patients with DLBCL had increased extranodal involvement and more advanced lymphoma stage at presentation than DLBCL patients in general, and the prognosis was poor. A further subdivision of DLBCL into germinal centre (GC) and non-GC subtypes by the expression patterns of CD10, bcl-6 and IRF-4 showed a predominance of the non-GC subtype. This suggested peripheral activated B-cells as the cells of origin in these lymphomas. The presence of EBV was low in lymphomas in RA patients (12%).
285

Barrandel och fukthalt i färsk grot från gran i södra Sverige / Needle and moisture content in fresh logging residues from Norway spruce in the south of Sweden

Keisu, Tanja January 2015 (has links)
Skogen är en förnyelsebar energikälla som möjliggör för ett minskat beroende av fossila bränslen. Ur ett politiskt perspektiv minskar såväl klimatpåverkan som beroendet av importerad energi från oroliga delar av världen genom att ta tillvara skogsbränsle lokalt. I Sverige är sågverkens biprodukter fullt utnyttjade och därför har skogsbränsle i from av grot (GRenar Och Toppar) en av de största potentialerna till ökat uttag. Barrträdens barr är en omstridd fråga i samband med tillvaratagandet av grot. Barren står för en liten del av biomassan, men för en stor del av näringen i ett bestånd. Därför är det önskvärt att så mycket som möjligt av barren lämnas på föryngringsytan. Om barrandel i färsk grot är känd kan den även användas för att beräkna hur mycket barr som egentligen lämnas kvar på hygget. Den energiomvandlande industrin vill inte heller ha för mycket barr i bränslet, då de anses skapa problem i förbränningen. Studien är ett fältexperiment genomförd på tio olika hyggen i södra Sverige under mars och april 2015. En grothög lastades på ett personbilssläp och transporterades till företaget Skogsbränsle Smålands flishugg för sönderdelning. Provmaterialet bearbetades sedan på Linnéuniversitetet där bl.a. fukthalt och barrandel bestämdes. Resultatet i denna studie genomförd i södra Sverige pekar på att medelvärdet för barrandelen i färsk grot från gran är 22,2 %, men där variationen mellan olika hygge kan variera stort (17,5–32,4 %). Medelvärdet ligger dock i nedre delen av det vedertagna intervallet motsvarande 20–30 %. Studien visade på ett medelvärde för fukthalt på 38,7 %, vilket är lägre än vad tidigare studier fastställt. Barrträd har lägst fukthalt under vårvintern, dvs. under genomförandet av denna studie vilket kan förklara en relativt låg fukthalt som annars generellt brukar vara 50–55 %. Denna studie har konstaterat att barrandelen för färsk grot från gran i södra Sverige är lägre än vedertaget intervall för hela Sverige. Det har även kunnat konstateras att det förekommer stora lokala avvikelser i barrandel, varför slutsatsen dras att det inte är rätt att anta ett generellt värde för barrandelen. Ett generellt antagande innebär t.ex. att bedömningen av hur mycket barr som lämnats kvar på föryngringsytan blir missvisade. Den ursprungliga barrandelen har en stor inverkan på hur mycket barr som lämnas kvar. Vidare har denna studie fastställt att fukthalten för grot från gran är lägre under vårvintern. / The forest is a renewable source of energy, enabling a reduction in dependence on fossil fuels. From a political point of view both climate impact as the dependence on imported energy from troubled parts of the world can be reduced by making use of forest fuel locally. In Sweden sawmill byproducts are fully exploited and therefore there is a potential to increase the proportion of forest fuels, particularly the removal of logging residues in form of branches and tops. Needles is a contentious issue in connection with the utilization of logging residues. The needles accounts for a small proportion of the biomass, but for a large part of the nutrients in a forest stand. Therefore, it is desirable that as much needles as possible is left in the harvesting area. If the needle proportion in fresh logging residues is known, it can also be used to calculate how much needles actually is left in the harvesting area. The energy converting industry does not want too much needles in the fuel, as it seems to create problems with combustion. The study is a field experiment conducted on 10 different harvesting areas in southern Sweden during March and April 2015. A pile of logging residues were loaded on a car trailer and then transported to Skogsbränsle Småland's chipper for decomposition. The test material was then processed at Linnaeus University, where needle and moisture content was determined. The results of this study conducted in the south of Sweden indicate that the average value of the needle content in fresh logging residues from spruce in southern Sweden is 22.2 %. The variation between different harvesting areas can vary greatly (17,5–32,4 %). This study showed a mean moisture content of fresh logging residues from spruce in southern Sweden of 38.7 %, which is lower than previous studies found. Softwood has the lowest moisture during early spring, during the implementation of this study, which may explain a relatively low moisture content which otherwise generally tend to be 50–55 %. This study found that the needle content in fresh logging residues from spruce in the south of Sweden is lower than the established range of 20–30 %. It has also been noted that there are large local variations in the needle content, therefore concluded that it is not right to adopt an overall value of the needle content. A general adoption of the needle content means e.g. that the assessment of how much needles left on the harvesting area becomes misleading. The needle content in fresh logging residues has a great impact on how much needles is left. Furthermore, this study found that the moisture content of logging residues from spruce is lower during early spring. / Metsä on uusiutuva energianlähde, jolla on mahdollista vähentää riippuvuutta fossiili polttoaineista. Poliittisesta näkökulmasta metsäpolttoaine vähentää sekä ilmastovaikutusta kuin tuontienergian riippuvaisuutta peräisin levottomista osista maailmaa. Ruotsissa sahan sivutuotteita hyödynnetään täysimääräisesti, siksi on iso mahdollisuus nostaa metsäpolttoaineiden osuutta, erityisesti hakkuutähteiden oksia ja latvoja. Havupuiden neulaset on kiistanalainen kysymys. Neulasten osuus on pieni osa metsän biomassasta, mutta suuri osa ravinteesta. On toivottavaa että niin paljon neulasia kuin mahdollista jätetään hakkuupaikalle. Energiateollisuus ei halua neulasia polttoaineeseen, koska se näyttää luovan ongelmia poltossa. Osuus neulasia tuoreissa hakkuutähteissä käytetään arvioimaan kuinka paljon neulasia todellisuudessa jää hakkuupaikalle. Tutkimus on kenttäkoe suoritettu kymmenellä eri hakkuupaikalla Etelä-Ruotsissa maalis-huhtikuun aikana 2015. Yksi kasa hakkuutähteitä lastattiin auton perävaunuun ja kuljetettiin Skogsbränsle Småland:in hakkurille hajottamista varten. Testimateriaali käsiteltiin sitten Linnaeus yliopistossa, jossa muun muassa osuus neulasia ja kosteuspitoisuus määritettiin. Tämän tutkimuksen tulokset osoittavat, että osuus neulasia tuoreissa hakkuutähteissä kuusesta Etelä-Ruotsissa on 22,2 %, mutta osuus eri hakkuupaikoilla vaihtelee suuresti (17,5–32,4 %). Yleinen arvo Ruotsissa on 20–30 %. Tämä tutkimus osoittaa myös, että kosteuspitoisuus tuoreissa hakkuutähteissä kuusesta Etelä-Ruotsissa on 38,7 %, joka on vähemmän kuin aiemmissa tutkimuksissa todettu. Havupuilla on alhaisin kosteus kevättalvella, samaan aikaan kun tämän tutkimuksen kenttätyö. Tämä voi selittää suhteellisen alhaisen kosteuspitoisuuden, joka muutoin yleensä pyrkii olemaan 50–55 %. Tutkimuksessa todettiin, että osuus neulasia tuoreissa hakkuutähteissä kuusesta Etelä-Ruotsissa on alempi kuin koko Ruotsin yleinen arvo. On myös todettu, että on olemassa suuria paikallisia vaihteluja hakkutähteiden neulasten osuudessa. Siksi päätellään, ettei ole oikein käyttää yleistä arvoa. Alkuperäisellä neulasosuudella on suuri vaikutus siihen, miten paljon neulasia on jätetty. Lisäksi tässä tutkimuksessa todettiin, että kuusen hakkutähteiden kosteuspitoisuus on alhaisempi kevättalvella.
286

Modern architecture + art : an analysis of preservation strategies for installed art / Modern architecture plus art / Modern architecture and art

Félix Marín, Tahinee M. 25 July 2011 (has links)
The purpose of this Master’s Report was to determine an appropriate preservation strategy for a particular set of buildings and their accompanying art from the Modern Architecture Movement. The research question was: What type of strategy is best suited for the preservation of installed art created for Modern style buildings? The study analyzed preservation strategies afforded to Modern art and architecture during rehabilitation of the buildings. The case studies are Modern Movement office or bank buildings with art commissioned for the space by the architects or owners. An analysis of the main case study’s preservation strategies looks at all the actions taken and proposed to protect, not only the material fabric of the art, but the primary interior space. The main case study was the American National Bank building in Austin, Texas designed by Kuehne, Brooks and Barr Architects with a mural by Seymour Fogel. The secondary case studies were: Harry Bertoia sculpture + Manufacturers Trust Building, New York City, Pietro Belluschi mural + Equitable Building, Portland, Oregon, Richard Lippold sculpture + Inland Steel Building, Chicago, and Roger Darricarrere dalle de verre + Columbia Savings Buildings, Los Angeles. After study and analysis, the preservation strategies were categorized in four categories: in situ conservation, removal, recreation/replacement and demolition/destruction. It was concluded that there is not a general approach for these projects, and each should be analyzed through various factors (Design Intent, Intrinsic Value, Collaboration and Context) to determine the appropriate intervention. / text
287

EBV-Specific CD4+ T Cell Responses in Acute Infectious Mononucleosis: a Dissertation

Precopio, Melissa Lynn 01 April 2004 (has links)
Epstein-Barr virus (EBV) is a ubiquitous herpesvirus that establishes a life-long latent infection of B cells. It is usually asymptomatic in healthy individuals; however, individuals with compromised immunity often develop EBV-induced lymphoma. EBV also encodes potential oncogenes that can contribute to tumorigenesis. Therefore, vaccine and immunotherapeutic strategies targeting EBV are desirable. Recent studies have shown that infusion of EBV-specific CD8+T cells can elicit remission of lymphomas arising after administration of immunosuppressive drugs during transplantation, suggesting an important role for T cells in the prevention of EBV-induced malignancy. A better understanding of the cellular immune components involved in the control of EBV will aid in the development of methods to prevent infection and/or treat EBV-associated disease. While EBV infection is usually acquired asymptomatically during childhood, primary infection of adolescents and young adults can result in an illness termed acute infectious mononucleosis (AIM). Because of the characteristic symptoms of the illness, individuals with AIM can be readily identified and diagnosed with acute EBV infection. Thus, primary CD4+ and CD8+ T cell responses against the virus can be evaluated. It has been previously found that there is a marked expansion of lytic EBV protein-specific CD8+ T cells early during AIM, with delayed detection of lower frequencies of latent EBV protein-specific CD8+ T cells. The magnitude and specificity of CD4+T cell responses during AIM has been less well characterized. This thesis dissertation presents data from both functional assays and direct staining experiments documenting the timing, magnitude, and antigen-specificity of CD4+ T cells over the course of primary EBV infection. Lytic and latent protein-specific CD4+ T cells were readily detected by intracellular IFN-γ production at presentation with AIM and declined rapidly thereafter. Blood EBV load was also quantitated and found to decrease over time following AIM. By contrast, CD8+T cell IFN-y responses remained high for several weeks following presentation with AIM. Direct staining of lytic epitope-specific CD4+ T cells during AIM revealed high frequencies of virus-specific cells with low proliferative and IFN-γ-producing potential. Blood EBV load in these patients was persistently high through 6 wk following AIM. These data suggest a relationship between high EBV load during acute infection and impaired EBV-specific CD4+ T cell responses, which are compatible with impaired CD4+ T cell responses reported during high viremia associated with other viral infections. This may represent a mechanism by which persistent viruses, such as EBV, are able to establish a life-long infection in their hosts.
288

Vectorisation de molécules biologiques par la protéine ZEBRA du Virus Epstein-Barr : applications en thérapie humaine / Optimization of ZEBRA protein as an innovative delivery system for therapeutic molecules

Marchione, Roberta 04 June 2014 (has links)
La compréhension des mécanismes moléculaires de différentes pathologies a permis la caractérisation de gènes et de protéines impliqués dans la pathogénèse et l'identification de cibles thérapeutiques intracellulaires. La nature hydrophobique de la membrane cellulaire empêche le passage des médicaments dans les cellules. Les Cell-Penetrating Peptides (CPP) ou domaines de transduction protéiques (PTD) sont des peptides qui permettent l'internalisation de macromolécules hydrophiles in cellulo et in vivo. Un nouveau peptide issu du facteur de transcription ZEBRA du virus Epstein-Barr, et qui possède des propriétés de transduction a été caractérisé récemment dans notre laboratoire. Des études par mutagénèse de délétion de la protéine ZEBRA ont permis d'identifier la région d'acides aminés (nommé ainsi MD) impliquée dans la pénétration cellulaire. Ce peptide traverse les membranes des cellules de mammifères par un mécanisme de translocation directe, même lorsqu'il est fusionné à des molécules telles que la protéine reportrice eGFP. Le mécanisme de pénétration directe représente un grand avantage pour les applications thérapeutiques: les molécules cargos peuvent être internalisées directement dans le cytoplasme cellulaire sans dégradation et sous une forme biologiquement active. L'objectif de cette thèse est d'étudier les propriétés de pénétration cellulaire du peptide MD et d'évaluer ses applications thérapeutiques comme système de vectorisation des protéines. Ce travail est structuré en trois parties. La première partie porte sur l'étude de l'optimisation de la séquence peptidique MD par réduction de taille et l'évaluation du rôle de sa composition en acides aminés dans le processus de translocation à travers la membrane cellulaire. Cette étude a conduit à l'identification d'une séquence plus courte MD (MD11) possédant une efficacité et un mécanisme de translocation inchangés. La deuxième partie décrit une approche thérapeutique basée sur MD11 visant à la complémentation protéique d'un dysfonctionnement identifiée dans la plupart des cancers. Les cellules tumorales présentent des altérations dans la machinerie de traduction résultant dans une prolifération cellulaire incontrôlée. Parmi les différents facteurs intervenant dans la régulation de ce processus, le facteur eucaryote d'initiation 3 (eIF3) contribue à l'oncogenèse et au maintien de l'état cancéreux. Ce complexe est composé de 13 sous-unités, désignées eIF3 a-m. L'expression de certaines sous-unités est altérée dans plusieurs cancers, et en particulier la sous-unité f (eIF3f) est significativement diminuée dans le mélanome, les cancers du pancréas, de la vulve, du sein, de l'intestin et de l'ovaire. L'expression ectopique par transfection transitoire du gène eIF3f inhibe la synthèse protéique et induit l'apoptose dans le mélanome et dans les cellules cancéreuses pancréatiques. A partir de ces observations, nous avons développé une approche thérapeutique innovante pour le traitement des cancers dans lesquels la protéine manquante eIF3f est produite sous forme recombinante fusionnée à la séquence de MD11, et ensuite internalisée dans les cellules cibles tumorales. Ces résultats démontrent que le système de transfert de eIF3f basé sur MD11 représente une stratégie efficace pour supprimer la prolifération des cellules tumorales. La dernière partie de cette thèse explore la propriété de pénétration de MD11 dans les cellules de levure, et en particulier dans le champignon pathogène Candida albicans. Les résultats obtenus démontrent la polyvalence de MD11, qui fonctionne comme vecteur de protéines à activité biologique aussi bien dans la levure que dans les cellules de mammifères. Le potentiel de MD11 comme système de transport et de relargage des protéines a donc été établis, toutefois certaines améliorations en ce qui concerne la formulation des protéines de fusion et des études in vivo doivent être réalisées afin de valider son efficacité thérapeutique. / In recent years, the understanding of disease molecular mechanisms has led to the identification of genes and proteins that are altered in disease state and many therapeutic targets have been found located within cells. The protective and hydrophobic nature of plasma membrane prevents therapeutic drugs from entering cells. Cell-penetrating peptides (CPPs) or protein transduction domains (PTDs) have emerged as a group of non-invasive delivery vectors for various hydrophilic macromolecules, and several in vitro and in vivo applications as pharmaceutical carriers have been reported. A novel cell-penetrating peptide deriving from the Epstein-Barr virus ZEBRA transcription factor has been recently characterized in our laboratory. A reductionist study of full-length ZEBRA protein has allowed to identify the amino acid region (named as Minimal Domain, MD) implicated in cellular uptake. This peptide is able to cross the mammalian cell membranes via a direct translocation mechanism even when fused to cargo molecules such as eGFP reporter protein. The direct penetration mechanism represents a great advantage for therapeutic applications as the cargo molecules can be directly delivered into cells cytoplasm in a biological active form. The aim of this thesis is to explore the cell-penetrating properties of the MD peptide and evaluate its applications as therapeutic protein delivery system. This work is structured in three parts.The first part describes the study on the optimization of MD peptide sequence by size-reduction and the evaluation of its amino acid composition role in the translocation process across the cell membrane. This study has led to the identification of a shorter MD sequence (MD11) with unvaried mechanism of translocation. The second section describes a MD11-based therapeutic approach aiming at repair a dysfunction of the protein synthesis identified in most cancers. The regulation of the protein synthesis has a crucial role in governing the eukaryotic cell growth and subtle defects in the translational machinery can alter the cellular physiology and lead to cell malignancy. Among the different factors intervening in the regulation of this process, the eukaryotic initiation factor 3 (eIF3) contributes to oncogenesis and maintenance of the cancer state. This complex is composed of 13 subunits (designated eIF3 a-m). The expression of eIF3 subunits is altered in several cancers, and in particular the f subunit (eIF3f) is significantly down-regulated in pancreas, vulva, breast, melanoma, ovary and small intestine tumors. The eIF3f ectopic expression by transient gene transfection inhibits cellular protein synthesis and induces apoptosis in melanoma and pancreatic cancer cells. Starting from these observations, we developed an innovative therapeutic approach for cancer treatment in which the missing eIF3f protein is produced in vitro in fusion to MD11, and delivered to cells. These results have demonstrated that the MD11- based eIF3f transfer system may represent a powerful strategy to suppress the tumor-cell proliferation. The last part of this thesis explores the cell-penetrating property of MD11 in yeast cells, and in particular in the pathogenic fungus Candida albicans. The presented results demonstrate the versatility of MD11, functioning as vectors in both yeast and mammalian cells and as carrier for proteins with biological activity.The MD11 potential as protein delivery system is evident; however some improvements regarding the fusion protein formulation and in vivo studies should be realized to validate the effectiveness of its therapeutic application.
289

Conserved Features of the T Cell Receptor Repertoire Contribute to the Persistence of EBV-Specific CD8 T Cells

Kamga, Larisa 14 June 2019 (has links)
Epstein-Barr Virus (EBV) is a ubiquitous human virus linked to several diseases, including cancers. CD8 T cells are important for controlling EBV replication. Generation and maintenance of virus-specific CD8 T cells is dependent on specific interaction between MHC-peptide complexes on the infected cell and the CD8 T cell receptor (TCR). Several lines of evidence suggest that the TCR repertoire is an essential component of the CD8 T-cell immune response. The current work focuses on delineating the features of the TCR repertoire that drive the selection of EBV-specific CD8 T cells into the memory phase. We used bulk and single-cell TCRαβ sequencing to analyze the TCR repertoire of human CD8 T cells specific for two immunodominant HLA-A02:01-restricted EBV-derived epitopes: BRLF1109-117 (YVLDHLIVV) and BMLF1280-288 (GLCTLVAML) during the acute and memory phases of primary EBV infection in humans. We showed that persistent EBV-specific clonotypes accounted for only 9% of unique clonotypes but were highly expanded in acute EBV infection and more commonly expressed identifiable features than non-persistent clonotypes. The other 91% of highly diverse unique clonotypes disappeared and were replaced in convalescence by equally diverse “de-novo” clonotypes. We provide evidence suggesting that recognition of BRLF1109-117may be driven by the TCRα. We identified a highly dominant and degenerate BRLF1109-117-specific TCRα sequence, AV8.1-CAVKDTDKLIF-AJ34, that was shared by all donors studied and identified conserved residues within this sequence that were important for antigen recognition. These findings are relevant to current efforts to develop or optimize the efficacy of T cell based therapies or vaccines.
290

We Are Not as Manly as We Pretend

Koss, Andrew 21 April 2021 (has links)
No description available.

Page generated in 0.3809 seconds